Previous 10 | Next 10 |
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that Alan H. Auerbach, Chairman, Chief Executive Officer, President and Founder of Puma, will provide an overview of the Company at 10:00 a.m. EDT on Tuesday, March 12 at the Cowen and Company 39th Annual Health ...
March 4, 2019 Palm Beach, FL – (March 4, 2018) – Medical technology is an area where the U.S. companies are at the forefront. In fact, according to recent industry publication the: “U.S. remains the largest medical device market in the world, with a market size of ...
Puma Biotechnology ( PBYI ) has been a name which attracted my interest in November as it reported dismal growth, yet I saw some room for silver linings at the start of November. Given that October sales numbers were already reported at the time, I was not surprised to see relatively solid Q...
Gainers: Bio-Path Holdings (NASDAQ: BPTH ) +130% . Puma Biotechnology (NYSE: PBYI ) +42% . Lexicon Pharmaceuticals (NASDAQ: LXRX ) +30% . GlobalSCAPE (NYSEMKT: GSB ) +29% . Castlight Health (NYSE: CSLT ) +24% . Farfetch Limited (NYSE: FTCH ) +23% . Sequential Brands Group (NASD...
Puma Biotechnology (NYSE: PBYI ) +30% on Q4 earnings . More news on: Puma Biotechnology, Inc., Funko, Inc., The Gap, Inc., Stocks on the move, Read more ...
Puma Biotechnology, Inc. (PBYI) Q4 2018 Earnings Conference Call February 28, 2019 4:30 PM ET Company Participants Mariann Ohanesian – Senior Director-IR Alan Auerbach – Chief Executive Officer, President and Chairman of the Board Steve Lo – Chief Commercial ...
Puma Biotechnology (NYSE: PBYI ) Q4 results ($M): Revenues: 71.1 (+229.2%); Nerlynx sales: 61.1 (+204.0%). More news on: Puma Biotechnology, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Puma Biotechnology (NYSE: PBYI ): Q4 Non-GAAP EPS of -$0.32 beats by $0.37 ; GAAP EPS of -$0.80 misses by $0.11 . Revenue of $71.1M (+229.2% Y/Y) beats by $17.45M . Shares +11.5% . Press Release More news on: Puma Biotechnology, Inc., Earnings news and commentary, Stocks on the...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the fourth quarter and year ended December 31, 2018. Unless otherwise stated, all comparisons are for the fourth quarter and full year 2018, compared to the fourth quarter and full year 2017...
SALT LAKE CITY, Feb. 28, 2019 (GLOBE NEWSWIRE) -- Predictive Technology Group, Inc. (OTC PINK: PRED), a leader in the use of data analytics for disease identification and subsequent therapeutic intervention through precision therapeutic treatments, announces that Jay M. Moyes has been named...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...